InnoCare Pharma News

Nuocheng Jianhua (9969.HK): Equity incentives highlight confidence in development and enter a new era of rapid 2.0 development

Southwest SecuritiesNov 27 00:00

Nuocheng Jianhua (688428): Oncology Immunity Two Blossoming Companies have entered a period of rapid growth

caitongNov 18 10:26

Nuocheng Jianhua (9969.HK): Revenue exceeds expectations and the self-exemption pipeline progresses smoothly

gtjaNov 13 07:42

INNOCARE PHARMA LIMITED(09969.HK):STRONG SALES PERFORMANCE IN 3Q24

Nov 12 19:27

Nuochengjianhua (688428): Sales of obutinib slightly exceeded expectations, and the annual sales guide was further raised to 45% year-on-year growth

Ping An Bank InternationalNov 12 00:00

Jefferies Sticks to Its Buy Rating for InnoCare Pharma Ltd. (9969)

TipRanksOct 27 20:17

Nuochengjianhua (688428) Company's First Coverage Report: Global Hematoma Leaders Open a Second Growth Curve

Open Source SecuritiesOct 25 00:00

UBS Group: Raises Innocare's target price to 8.6 Hong Kong dollars, maintains a "buy" rating.

Gelonghui FinanceOct 14 15:45

UBS Group: Maintains a "buy" rating on Innocare (09969) with a target price raised to 8.6 Hong Kong dollars.

Zhitong FinanceOct 14 15:40

Nuochengjianhua (688428): A complete breakthrough in the variant TYK2 inhibitor with excellent psoriatic phase 2 data immunity pipeline

The Pacific SecuritiesOct 14 00:00

Research reports dig gold丨gtja: innocare ICP-488 domestic progress leading, chronic disease pipeline accelerated advancement.

Gelonghui FinanceOct 12 15:02

Nuochengjianhua (9969.HK): 488 excellent clinical data, accelerated progress of the chronic disease pipeline

gtjaOct 12 07:51

Nuocheng Jianhua (9969.HK): Phase MSIII received FDA approval to open overseas space

Sep 9 13:46

InnoCare Pharma Ltd. (9969) Gets a Buy From Jefferies

TipRanksSep 4 20:22

Furui: Maintains a "buy" rating for Innocare (09969) with a target price cut to HK$12.

Zhitong FinanceSep 4 10:44

Nuochengjianhua (9969.HK): Obutinib continues to grow and injects new vitality into the solid tumor sector

中信建投證券Aug 26 11:06

Nuochengjianhua-U (688428) 2024 Interim Report Review: Obutinib Q2 sales increased 49% year-on-year, raised the annual sales growth guide to 35%

Aug 23 19:11

Nuochengjianhua (9969.HK): The innovative pipeline for accelerated release of obutinib progresses smoothly

Aug 23 13:11

Nuochengjianhua (688428): Strong growth of obutinib, further narrowing of losses

Aug 22 15:06

Nuochengjianhua (688428): Obutinib 24Q2 increased 49% year-on-year, MZL Health Insurance exclusively helps rapid dosage

Aug 22 00:00